Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KIT | P10721 | 12/20 | 0.51 |
| ▸ | CLK2 | P49760 | 1/20 | 0.48 |
| ▸ | CLK3 | P49761 | 1/20 | 0.48 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.48 |
| ▸ | RET | P07949 | 4/20 | 0.47 |
| ▸ | AURKA | O14965 | 2/20 | 0.44 |
| ▸ | AURKB | Q96GD4 | 2/20 | 0.44 |
| ▸ | INCENP | Q9NQS7 | 2/20 | 0.44 |
| ▸ | TPX2 | Q9ULW0 | 2/20 | 0.44 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20928388 | 0.92 | KIT (0.49) | KITCLK2CLK3DYRK1ARET | |
| SCHEMBL22568621 | 0.90 | KIT (0.51) | KITRETAURKAAURKBINCENP | |
| SCHEMBL20927905 | 0.88 | KIT (0.53) | KITCLK2CLK3DYRK1ARET | |
| SCHEMBL20928313 | 0.87 | KIT (0.49) | KITCLK2CLK3DYRK1ARET | |
| SCHEMBL20927801 | 0.86 | KIT (0.49) | KITCLK2CLK3DYRK1ARET | |
| SCHEMBL22568631 | 0.86 | KIT (0.48) | KITRETAURKAAURKBINCENP | |
| SCHEMBL20928120 | 0.86 | KIT (0.50) | KITCLK2CLK3DYRK1ARET | |
| SCHEMBL22568655 | 0.86 | KIT (0.50) | KITCLK2CLK3DYRK1ARET | |
| SCHEMBL20927781 | 0.86 | KIT (0.50) | KITCLK2CLK3DYRK1AAURKA | |
| SCHEMBL22568642 | 0.85 | KIT (0.51) | KITCLK2CLK3DYRK1AAURKA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11236086-B2 | Substituted pyrrolopyridines as inhibitors of activin receptor-like kinase | BLUEPRINT MEDICINES CORPORATION (US) | 2022-02-01 | — | — | US | disclosed |
| US-20200331908-A1 | SUBSTITUTED PYRROLOPYRIDINES AS INHIBITORS OF ACTIVIN RECEPTOR-LIKE KINASE | BLUEPRINT MEDICINES CORPORATION | 2020-10-22 | — | — | US | disclosed |
| WO-2019079649-A1 | SUBSTITUTED PYRROLOPYRIDINES AS INHIBITORS OF ACTIVIN RECEPTOR-LIKE KINASE | BLUEPRINT MEDICINES CORPORATION (US) | 2019-04-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11236086-B2 | Substituted pyrrolopyridines as inhibitors of activin receptor-like kinase | ALK, ACVR1, ACVR2A | KIT 318/4885CLK2 787/4885CLK3 1183/4885 |
| US-20200331908-A1 | SUBSTITUTED PYRROLOPYRIDINES AS INHIBITORS OF ACTIVIN RECEPTOR-LIKE KINASE | ALK, ACVR1, ACVR2A | KIT 318/4885CLK2 787/4885CLK3 1183/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.